Page 276 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 276
Viral Hepatitis: Hepatitis C - Clinical (New Compounds, Resistance) (Cont.)
P0893 RESISTANCE ANALYSIS OF TREATMENT-EXPERIENCED
GENOTYPE 1 AND 3 HCV INFECTED PATIENTS TREATED
WITH SOFOSBUVIR IN COMBINATION WITH GS-5816 ±
RIBAVIRIN FOR 12 WEEKS
Brian P. Doehle*, Evguenia S. Svarovskaia, Krishna Chodavarapu,
John McNally, Stephen Pianko, Stuart K. Roberts, Diana M. Brainard,
Michael D. Miller, Hongmei Mo, The United States
P0894 PREVALENCE OF PRE-TREATMENT NS5A AND NS5B
RESISTANCE ASSOCIATED VARIANTS AND GENETIC
VARIATION WITHIN HCV SUBTYPES ACROSS DIFFERENT
COUNTRIES
Evguenia Svarovskaia*, Stefan Zeuzem, Charlotte Hedskog, Ross
Martin, Diana M. Brainard, Michael D. Miller, Ed Gane, Hongmei Mo,
The United States
P0895 COMPARISON OF THREE SEQUENCING METHODS
COMMONLY USED IN HEPATITIS C VIRUS RESISTANCE
ePOSTERS ANALYSIS: POPULATION-BASED VS. CLONAL VS. ULTRA
DEEP SEQUENCING
Simone Susser*, Bastian Beggel, Dany Perner, Caterina Berkowski,
Stefan Zeuzem, Thomas Lengauer, Christoph Sarrazin, Germany
P0896 LONG-TERM FOLLOW-UP ANALYSIS OF RAVS IN HCV NS3,
NS5A, AND NS5B IN DAA THERAPY FAILURE PATIENTS
Simone Susser*, Judith Würzburg, Stefan Kofler, Tania M. Welzel,
Dany Perner, Stefan Zeuzem, Christoph Sarrazin, Germany
P0897 EFFICACY OF SIMEPREVIR AND SOFOSBUVIR FOR
TREATMENT OF CIRRHOTIC PATIENTS WITH GENOTYPE 1
CHRONIC HEPATITIS C - A SINGLE CENTER EXPERIENCE
Vandana Singh*, Todd Frederick, Edward W. Holt, Adil E. Wakil,
Jennifer Guy, Raphael B. Merriman, Timothy J. Davern, Kidist K. Yimam,
Chanda K. Ho, Tammy K. Lee, Stewart L. Cooper, The United States
P0898 TD-6450, A NEXT GENERATION ONCE-DAILY NS5A
INHIBITOR, HAS POTENT ANTIVIRAL ACTIVITY
FOLLOWING A 3-DAY MONOTHERAPY STUDY IN
GENOTYPE 1 HCV INFECTION
Eric Lawitz*, Maribel Rodriguez-Torres, Roger Kohler,
Aniruddha Amrite, Chris Barnes, Maria Lucia C. Pecoraro, Joe Budman,
Murray McKinnell, Carla B. Washington, The United States
276 The International Liver Congress™ 2015 • ILC Programme
P0893 RESISTANCE ANALYSIS OF TREATMENT-EXPERIENCED
GENOTYPE 1 AND 3 HCV INFECTED PATIENTS TREATED
WITH SOFOSBUVIR IN COMBINATION WITH GS-5816 ±
RIBAVIRIN FOR 12 WEEKS
Brian P. Doehle*, Evguenia S. Svarovskaia, Krishna Chodavarapu,
John McNally, Stephen Pianko, Stuart K. Roberts, Diana M. Brainard,
Michael D. Miller, Hongmei Mo, The United States
P0894 PREVALENCE OF PRE-TREATMENT NS5A AND NS5B
RESISTANCE ASSOCIATED VARIANTS AND GENETIC
VARIATION WITHIN HCV SUBTYPES ACROSS DIFFERENT
COUNTRIES
Evguenia Svarovskaia*, Stefan Zeuzem, Charlotte Hedskog, Ross
Martin, Diana M. Brainard, Michael D. Miller, Ed Gane, Hongmei Mo,
The United States
P0895 COMPARISON OF THREE SEQUENCING METHODS
COMMONLY USED IN HEPATITIS C VIRUS RESISTANCE
ePOSTERS ANALYSIS: POPULATION-BASED VS. CLONAL VS. ULTRA
DEEP SEQUENCING
Simone Susser*, Bastian Beggel, Dany Perner, Caterina Berkowski,
Stefan Zeuzem, Thomas Lengauer, Christoph Sarrazin, Germany
P0896 LONG-TERM FOLLOW-UP ANALYSIS OF RAVS IN HCV NS3,
NS5A, AND NS5B IN DAA THERAPY FAILURE PATIENTS
Simone Susser*, Judith Würzburg, Stefan Kofler, Tania M. Welzel,
Dany Perner, Stefan Zeuzem, Christoph Sarrazin, Germany
P0897 EFFICACY OF SIMEPREVIR AND SOFOSBUVIR FOR
TREATMENT OF CIRRHOTIC PATIENTS WITH GENOTYPE 1
CHRONIC HEPATITIS C - A SINGLE CENTER EXPERIENCE
Vandana Singh*, Todd Frederick, Edward W. Holt, Adil E. Wakil,
Jennifer Guy, Raphael B. Merriman, Timothy J. Davern, Kidist K. Yimam,
Chanda K. Ho, Tammy K. Lee, Stewart L. Cooper, The United States
P0898 TD-6450, A NEXT GENERATION ONCE-DAILY NS5A
INHIBITOR, HAS POTENT ANTIVIRAL ACTIVITY
FOLLOWING A 3-DAY MONOTHERAPY STUDY IN
GENOTYPE 1 HCV INFECTION
Eric Lawitz*, Maribel Rodriguez-Torres, Roger Kohler,
Aniruddha Amrite, Chris Barnes, Maria Lucia C. Pecoraro, Joe Budman,
Murray McKinnell, Carla B. Washington, The United States
276 The International Liver Congress™ 2015 • ILC Programme
